Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for bl...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Weiss, Glen J., Tibes, Raoul, Blaydorn, Lisa, Jameson, Gayle, Downhour, Molly, White, Erica, Caro, Ivor, Von Hoff, Daniel D.
Médium: Artigo
Jazyk:Inglês
Vydáno: PAGEPress Publications 2011
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4211514/
https://ncbi.nlm.nih.gov/pubmed/25386306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/dr.2011.e55
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky